IN-111-OCTREOTIDE IMAGING IN PATIENTS WITH LONG-STANDING GRAVES OPHTHALMOPATHY

被引：19

作者：

BOHUSLAVIZKI, KH

OBERWOHRMANN, S

BRENNER, W

EBERHARDT, JU

MONIG, H

CLAUSEN, M

SIPPEL, C

WOLF, H

EPE, B

HENZE, E

机构：

[1] Clinics of Nuclear Medicine, Christian-Albrechts-Universitat Kiel, Kiel

[2] Clinics of Internal Medicine, Christian-Albrechts-Universitat Kiel, Kiel

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1995年 / 16卷 / 11期

关键词：

D O I：

10.1097/00006231-199511000-00006

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The aim of this study was to examine patients with long-standing Graves' ophthalmopathy using (111)Inoctreotide scintigraphy. Sixteen patients with inactive ophthalmopathy of up to 114 months duration and 14 normals were investigated for 48 h following an injection of 200 MBq In-111-octreotide. No significant tracer accumulation in the orbital region could be identified in any of the patients with long-standing Graves' ophthalmopathy. The orbit to brain (O/B) ratios after 24 and 48 h were 2.39 +/- 0.36 and 2.15 +/- 0.44 Versus 2.17 +/- 0.33 and 2.20 +/- 0.37 for the patients and normals, respectively (N.S.). In-111-octreotide accumulation in ophthalmopathy described in the literature may thus be a passing event limited to its active stage, which is consistent with the concept of imaging a lymphocytic infiltration. In this study, the lack of accumulation of In-111-octreotide in the orbital region during the inactive stage demonstrates an absence of somatostatin receptors in orbital tissue itself. Thus, in patients with inactive Graves' ophthalmopathy, there is no basis for a diagnostic approach with somatostatin.

引用

页码：912 / 916

页数：5

共 21 条

[11]

Classification of eye changes of Graves' disease, Thyroid, 2, pp. 235-236, (1992)

[12]

Werner S.C., Modification of the classification of the eye changes of Graves' disease: Recommendations of the ad hoc Commitee of the American Thyroid Association, J Clin Endocrinol, 44, pp. 203-205, (1977)

[13]

Byren S.F., Gendron E.K., Glaser J.S., Feuer W., Hatem A., Diameter of normal extraocular recti muscles with echo-graphy, Am J Ophthalmol, 112, pp. 706-713, (1991)

[14]

Sachs L., Applied Statistics: A Handbook of Techniques, (1984)

[15]

Becker W., Schrell U., Buchfelder M., Hensen M., Wendler J., Gramatzki M., Wolf F., Somatostatin receptor expression in the thyroid demonstrated with 11’In-octreotide scintigraphy, Nucl Med, 34, pp. 100-103, (1995)

[16]

Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breemann W., Kooij P., Oie H.Y., Van Hagen M., Postema P., De Jong M., Reubi J.C., Reijs A., Hofland L.J., Koper J.W., Lam-Berts S., Somatostatin receptor scintigraphy with [nlIn- DTPA-D-Phe’]- and [l23Tyr,]-octreotide: The Rotterdam experience with more than 1000 patients, Eur J Nucl Med, 20, pp. 716-731, (1993)

[17]

Kwekkeboom D.J., Krenning E.P., Bakker W.J., Oei H.Y., Kooij P., Lamberts S., Somatostatin analogue scintigraphy in carcinoid tumors, Eur Jnucl Med, 20, pp. 283-292, (1993)

[18]

Kwekkeboom D.J., Van Urk H., Pauw B., Lamberts S., Kooij P., Hoogma P., Krenning E.P., Octreotide scin-tigraphy for the detection of paragangliomas, J Nucl Med, 34, pp. 873-878, (1993)

[19]

Bahn R.S., Heufelder A.E., Pathogenesis of Graves' ophthal-mopathy, N Engl J Med, 329, pp. 1468-1475, (1993)

[20]

Hurley J.R., Orbitopathy after treatment of Graves' disease, J Nucl Med, 35, pp. 918-920, (1994)

← 1 2 3 →